Menu
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€44.29
-0.820%

Roche Bobois S.a.

WKN: A2JQRU / Name: Roche Bobois S.a. / Stock / ? /

?
-4.280%

Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

?
-3.770%

Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

?
-3.400%

Roche Finance Europe B.v.

WKN: A3LEL7 / Name: Roche Finance Europe B.v. / Stock / ? /

€102.31
0.070%

Roche Finance Europe B.v.

WKN: A3LEL8 / Name: Roche Finance Europe B.v. / Stock / ? /

€101.78
0.070%

Roche Finance Europe B.v.

WKN: A3LRTS / Name: Roche Finance Europe B.v. / Stock / ? /

€101.67
0.000%

Roche Finance Europe B.v.

WKN: A3LRTT / Name: Roche Finance Europe B.v. / Stock / ? /

€101.66
0.160%

Roche Finance Europe B.v.

WKN: A3LX6K / Name: Roche Finance Europe B.v. / Stock / ? /

€102.62
0.030%

Roche Finance Europe B.v.

WKN: A3LX6L / Name: Roche Finance Europe B.v. / Stock / ? /

€95.64
0.160%

Roche Holdings Inc.

WKN: A3LVX8 / Name: Roche Holdings Inc. / Stock / ? /

€97.84
0.510%

Roche Holding AG

WKN: A424UK / Name: Roche Holding / Stock / ? /

€350.00
-0.960%

Trading Roche Holding AG

Trading Roche Holding AG

FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for its investigational candidate, giredestrant, as an adjuvant treatment for adults with oestrogen receptor

Roche Holding (RHHBY) Upgraded to Buy: Here's What You Should Know
Roche Holding (RHHBY) Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Roche Holding AG (RHHBY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is

Rochefocauld
Account activated